Citigroup’s Cytokinetics CYTK Stock Holding History

Citigroup’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-60,000	Closed	-$3.81M	–	6031
2025 Q4	$3.81M	Buy	60,000 +35,000	+140%	+$2.18M	﹤0.01%	2215
2025 Q3	$1.37M	Sell	25,000 -5,000	-17%	-$206K	﹤0.01%	2959
2025 Q2	$991K	Sell	30,000 -65,500	-69%	-$2.28M	﹤0.01%	3201
2025 Q1	$3.84M	Sell	95,500 -1,300	-1%	-$59.7K	﹤0.01%	2152
2024 Q4	$4.55M	Sell	96,800 -700	-0.7%	-$36.4K	﹤0.01%	2060
2024 Q3	$5.15M	Buy	+97,500	New	+$5.43M	﹤0.01%	1820
2024 Q1	–	Sell	-30,000	Closed	-$2.5M	–	5676
2023 Q4	$2.5M	Buy	+30,000	New	+$1.09M	﹤0.01%	2053
2023 Q3	–	Sell	-55,000	Closed	-$1.79M	–	5692
2023 Q2	$1.79M	Sell	55,000 -29,400	-35%	-$1.09M	﹤0.01%	2316
2023 Q1	$2.97M	Buy	84,400 +54,400	+181%	+$2.22M	﹤0.01%	1767
2022 Q4	$1.37M	Buy	+30,000	New	+$1.29M	﹤0.01%	2336
2022 Q3	–	Sell	-20,000	Closed	-$786K	–	5917
2022 Q2	$786K	Buy	+20,000	New	+$805K	﹤0.01%	2871

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citigroup's CYTK Position: Q2 2026 in Review

Citigroup increased its Cytokinetics (CYTK) stake by 30% in Q2 2026, buying an estimated $5.29M and bringing the position to 322,932 shares worth $27.5M. The position accounts for 0.01% of the portfolio, ranked #1000.

Citigroup first reported a position in CYTK in Q2 2013 and has held it in 53 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Citigroup held 322,932 shares of Cytokinetics worth $27.5M as of Q2 2026.
Citigroup bought 73,689 Cytokinetics shares in Q2 2026, an estimated $5.29M.
Cytokinetics made up 0.01% of Citigroup's portfolio in Q2 2026, its #1000 holding.
Citigroup first reported a position in Cytokinetics in Q2 2013 and has held it in 53 quarters since.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.